R V Iaffaioli
Overview
Explore the profile of R V Iaffaioli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
331
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Iaffaioli R, Milano A, Caponigro F
Ann Oncol
. 2007 Sep;
18 Suppl 6:vi153-6.
PMID: 17591811
The methotrexate, vinblastine, doxorubicin, cisplatin (M-VAC) regimen has been considered as standard treatment of metastatic bladder carcinoma till recent years. The superiority of M-VAC both to cisplatin alone and to...
12.
Facchini G, Caraglia M, Nasti G, Ottaiano A, Franco R, La Mura A, et al.
Ann Oncol
. 2007 Sep;
18(9):1579-80.
PMID: 17761712
No abstract available.
13.
Pignata S, Pisano C, Di Maio M, Iodice F, Casella G, Laurelli G, et al.
Ann Oncol
. 2006 Jun;
17 Suppl 7:vii49-50.
PMID: 16760292
Epidemiologic analysis reveals that mortality rates from ovarian cancer are continuously decreasing due to the improvement of surgery and chemotherapy. However, overall, the prognosis of ovarian cancer patients is still...
14.
Facchini G, Fiore F, Caraglia M, DAngelo R, Nasti G, Caponigro F, et al.
Ann Oncol
. 2005 Jul;
16(12):1980-1.
PMID: 16033872
No abstract available.
15.
Iaffaioli R, Formato R, Tortoriello A, Del Prete S, Caraglia M, Pappagallo G, et al.
Br J Cancer
. 2005 Apr;
92(9):1621-5.
PMID: 15856035
Hormonal therapy is the preferred systemic treatment for recurrent or metastatic, post-menopausal hormone-receptor-positive breast cancer. Previous studies have shown that there is no cross-resistance between exemestane and reversible aromatase inhibitors....
16.
Strocchi E, Iaffaioli R, Facchini G, Mantovani G, Ricci S, Cavallo G, et al.
Eur J Surg Oncol
. 2004 Jul;
30(6):663-70.
PMID: 15256242
Aim: To verify the rationale of a pelvic stop-flow technique for the perfusion of high-doses of mitomycin C and anthacyclines in patients with inoperable, recurrent pelvic cancer. Methods: The stop-flow...
17.
Di Maio M, Gridelli C, Gallo C, Manzione L, Brancaccio L, Barbera S, et al.
Br J Cancer
. 2004 May;
90(12):2288-96.
PMID: 15162156
Pain is a highly distressing symptom for patients with advanced cancer. WHO analgesic ladder is widely accepted as a guideline for its treatment. Our aim was to describe pain prevalence...
18.
Di Maio M, Perrone F, Gallo C, Iaffaioli R, Manzione L, Piantedosi F, et al.
Br J Cancer
. 2003 Sep;
89(6):1013-21.
PMID: 12966418
The present study describes supportive care (SC) in patients with advanced non-small-cell lung cancer (NSCLC), evaluating whether it is affected by concomitant chemotherapy, patient's performance status (PS) and age. Data...
19.
Tambaro R, Greggi S, Iaffaioli R, Rossi A, Pisano C, Manzione L, et al.
Ann Oncol
. 2003 Sep;
14(9):1406-11.
PMID: 12954580
Background: The aim of this study was to determine the maximum tolerated dose (MTD) of liposomal doxorubicin (LD)-vinorelbine (V) in patients with refractory or resistant ovarian cancer. Patients And Methods:...
20.
Ottaiano A, Pisano C, De Chiara A, Barletta E, Ascierto A, Botti G, et al.
Anticancer Res
. 2003 Jun;
23(2B):1597-604.
PMID: 12820428
Background: CD40, a member of the tumor necrosis factor receptor superfamily, is capable of mediating the induction of apoptosis in tumors including sarcomas. The expression of proapoptotic receptor contribute to...